Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gain Therapeutics, Inc. - Common Stock (NQ: GANX )

1.560 -0.010 (-0.64%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 150,758
Open 1.550
Bid (Size) 1.550 (4)
Ask (Size) 1.840 (1)
Prev. Close 1.570
Today's Range 1.500 - 1.700
52wk Range 0.8900 - 5.330
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Gain Therapeutics To Present At Biotech Showcase 2025
Presentation to Feature Lead Drug Candidate GT-02287 and Magellan Drug Discovery Platform 
From Gain Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga

Performance

YTD
-56.97%
-56.97%
1 Month
-3.70%
-3.70%
3 Month
+0.65%
+0.65%
6 Month
+20.93%
+20.93%
1 Year
-36.84%
-36.84%

More News

Read More
Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2
From Gain Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate at Upcoming Investor Conferences
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers
From Gain Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Small-Cap Gain Therapeutics Stock Falls On Phase 1 Data From Its Lead Asset For Parkinson's Disease
Via Benzinga
Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
GANX Stock Earnings: Gain Therapeutics Misses EPS for Q2 2024
Via InvestorPlace
Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
7 Sorry Biotech Stocks Set to Make Investors Sad
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.